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ABSTRACT
Autologous HSCT has resulted in improved event-free survival in patients with advanced neuroblastoma, but
most of these patients still relapse. We previously reported that transient transfection of mouse neuroblastoma
cells with plasmid DNA vectors encoding immune costimulatory molecules generates cell-based vaccines
capable of inducing potent antitumor T cell immunity. In this study, we explored the effectiveness of tumor
vaccine administration soon after HSCT. Soon after transplantation, only vaccinated mice that had received an
adoptive transfer of syngeneic T cells survived tumor challenge. Tumor protective immunity in the transplant
recipients was dependent on CD4 and CD8 T cells, and tumor-reactive T cells in the spleens of vaccinated
mice could be detected in IFN- enzyme-linked immunosorbent spot (ELISPOT) assays. Our data indicate
that the adoptive transfer of T cells was absolutely required for induction of protective immunity by the tumor
vaccine. Adoptive transfer of T cells accelerated T cell reconstitution, but it also resulted in increased
percentages of CD4CD25Foxp3 cells soon after HSCT. Treatment of HSC transplant recipients with an
anti-CD25 mAb before tumor vaccination inhibited antitumor immunity and significantly decreased the
number of IFN--secreting tumor-specific CD4 T cells. However, physical depletion of CD25 cells from the
adoptively transferred splenocytes appeared to increase the efficacy of tumor vaccination. Collectively, these
results demonstrate that anti-neuroblastoma immunity can be induced soon after HSCT using a novel
cell-based cancer vaccine. However, sufficient numbers of T cells must be added to the graft to achieve
protective antitumor immunity, and depletion of CD25 T cells from adoptively transferred T cells might
provide some additional benefit. These translational studies will aid in our development of post-HSCT
vaccines for neuroblastoma.
© 2007 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Neuroblastoma is the most common extracranial
olid tumor in children, accounting for 8% of all
hildhood cancers [1]. It still has one of the highest
eath rates of all pediatric cancers and is responsible
or approximately 15% of childhood cancer deaths.
espite aggressive treatment, the outcome remains
oor for many patients with neuroblastoma. Autolo-
ous HSCT has resulted in improved event-free sur-
ival for patients with severe disease. However,50% tf patients develop recurrent neuroblastoma from re-
idual disease or from contaminating tumor cells in
utologous grafts. Because of the high incidence of
elapse, more effective treatments targeting minimal
esidual disease are required.
It has been demonstrated that neuroblastoma cells
xpress tumor antigens that might be recognized by
ytotoxic T cells [2-4]. However, in vivo the tumor
ay be poorly immunogenic due to an absence of
ritical immune costimulatory molecules. Neuroblas-
oma cells that have been genetically modiﬁed to ex-
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W. Jing et al.278ress various immune stimulatory molecules have
een employed to induce antitumor immunity in ex-
erimental animal models. Because individual immune
timulatory molecules might trigger diverse patterns of
ellular activation that contribute differentially to the
nduction and effector phases of the immune response,
ombinations of immune stimulatory molecules could
rovide synergistic or additive effects to tumor im-
une responses. Our experiments have demonstrated
ynergistic antitumor effects by combining the co-
timulatory molecules CD80 and CD86 or CD80 and
D137L (4-1BB ligand) [5,6]. We also showed that
igh-level transfection of neuroblastoma cells to ex-
ress a panel of 4 immune costimulatory molecules
CD54, CD80, CD86, and CD137L) transformed the
umor cells into a tumor vaccine capable of stimulat-
ng a potent T cell response [7]. This vaccine in-
reased the numbers of detectable tumor-speciﬁc
plenic CTLs in treated animals, and it induced a
ore effective antitumor response than did tumor
ells expressing only CD80 and CD86.
In this study we explored the effectiveness of tu-
or vaccine administration soon after high-dose ther-
py and HSCT because this may be an ideal setting to
nduce effective tumor immunity due to decreased
isease burden [8], altered immune regulation [9], and
ltered T cell homeostasis [10]. Accelerated lymphoid
econstitution of donor or host origin may overcome
nherent defects in T cell signaling [11], defects in
PC function including antigen processing and/or
resentation, or defective T cell costimulation by
PCs [12,13]. Manipulation of the T cell repertoire
y immunization during post-HSCT immune recon-
titution might skew the T cell repertoire toward
articular antigen speciﬁcities [14]. Results of animal
tudies have also suggested that vaccination during
omeostatic proliferation could facilitate an immune
esponse to weak self-antigens and enhance T cell-
ediated antitumor immunity [15-18].
The immediate post-HSCT period is accompa-
ied by immune deﬁciency as a result of smaller im-
une effector cell numbers and impaired lymphocyte
unction [10]. We hypothesized that efﬁcient antitu-
or immune responses could be induced soon after
SCT only if syngeneic T cells were adoptively trans-
erred at the time of transplantation. In this study, we
how that the combination of high-dose TBI, HSCT,
cell add-back, and early post-transplantation tumor
accination generates potent anti-neuroblastoma im-
unity in a manner that could be exploited in future
linical trials.
ETHODS
ice
The following strains of mice (6-8 wk of age) were
urchased from Jackson Laboratories (Bar Harbor, (e): A/J, C57BL/6 (B6) (CD45.2; Thy1.2),
ongenic B6.PL-Thy1a (CD45.2; Thy1.1), and B6-
5.1 (CD45.1; Thy1.2). The animals were housed
n the Medical College of Wisconsin Biomedical Re-
ource Center (Milwaukee, Wis), which has been ac-
redited by the American Association for Accredita-
ion of Laboratory Animal Care.
umor Cells
Neuro-2a, a mouse neuroblastoma of strain A or-
gin, was obtained from the American Type Culture
ollection (ATCC; Manassas, Va). The tumor cells
xpress MHC class I antigens, but are MHC class II
egative. An aggressive subclone, designated AGN2a,
as derived through sequential in vivo and in vitro
assaging [5]. An MHC class II AGN2a cell line
designated AGN2a-CIITA) was derived by stably
ransfecting AGN2a with a plasmid expression vector
pcDNA3.1[]; Invitrogen, Carlsbad, Calif) encoding
he MHC class II transactivator (CIITA) gene (pro-
ided by Dr Suzanne Ostrand-Rosenberg at The Uni-
ersity of Maryland, Baltimore County). SaI, a ﬁbro-
arcoma cell line derived from an A/J mouse, was
btained from the ATCC.
ntibodies
The following mAbs, with or without a ﬂuorescent
abel, were obtained from BD Biosciences (BD Bio-
ciences Pharmingen, San Diego, Calif): anti-CD4
clones GK1.5 and RM4-5), anti-CD8 (clone 53-6.7),
nti-CD16/CD32 (clone 2.4G2), anti-CD25 (clones
D4 and PC61), anti-CD45.1 (clone A20), anti-
D45.2 (clone 104), anti-CD54 (clone 3E2), anti-4-
BBL (clone TKS-1), anti-CD80 (clone 16-10A1),
nti-CD86 (clone 37.51), anti-CD90.2 (Thy1.2; clone
3-2.1), and anti-rat IgG2a (clone RG7/1.30). Control
ntibodies included puriﬁed mouse IgG2b and rat
gG2b. Anti-CD90.1 (Thy1.1, clone HIS51) and anti-
oxp3 (clone FJK-16s) mAbs were obtained from
Bioscience (eBioscience, San Diego, Calif ).
Hybridomas producing anti-CD25 mAb (clone
C61), anti-CD4 mAb (clone GK1.5), and anti-CD8
Ab (clone 2.43) were obtained from the ATCC.
hese mAbs were produced in our laboratory using
ntegra CL 1000 bioreactors (Chur, Switzerland).
nti-Thy1.2-, anti-CD4-, anti-CD8-, and anti-PE-
onjugated microbeads used for immunomagnetic cell
eparation were purchased from Miltenyi Biotec
Miltenyi Biotec, Auburn, Calif ).
Flow cytometry was used to analyze gene-modi-
ed AGN2a cells for cell surface expression of im-
une stimulatory molecules as described previously
7]. Antibody-stained cells were analyzed with a Bec-
on Dickinson FACScan ﬂow cytometer, and the re-
ulting data were analyzed using Flow-Jo software
Tree Star, San Carlos, Calif ).
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A/J spleens were collected and processed into sin-
le-cell suspensions. The splenocytes were incubated
ith anti-Thy1.2-, anti-CD8-, or anti-CD4-conju-
ated microbeads (Miltenyi Biotec), and the T cells
ere positively selected using a Miltenyi automated
mmunomagnetic sorter (autoMACS). The level of T
ell enrichment was determined by ﬂow cytometric
nalysis. The Thy1.2-enriched cells typically con-
isted of 95% T cells, and the purity of CD4- and
D8-enriched T cells was 98%. Alternatively,
D25 cells were physically depleted from spleno-
ytes by sequential incubation with PE-conjugated
nti-CD25 mAb (clone PC61) and anti-PE-conju-
ated microbeads (Miltenyi Biotec), followed by neg-
tive selection using an autoMACS cell sorter.
yngeneic HSCT and Tumor Vaccination
Femurs and tibiae were obtained from donor A/J
ice, and BM was harvested by ﬂushing the bones
ith DMEM. For HSCT, A/J recipient mice were
ethally irradiated (1100 cGy) and 24 h later given a
ingle i.v. injection of 107 BM cells with or without
-4  107 added splenocytes or 5  106 Thy1.2-
nriched T cells. In some experiments, the Thy1.2-
nriched T cells were administered 3 d after HSCT.
n other experiments, lethally irradiated (1000 cGy)
57BL/6 mice received transplants by i.v. injection
ith 107 BM cells from B6.PL-Thy1a mice plus 2 
07 splenocytes from B6-CD45.1 mice.
For vaccination, on days 7 and 14 after HSCT,
ecipient A/J mice were given subcutaneous injections
f 2  106 irradiated (5000 cGy) AGN2a cells. Ex-
erimental groups of mice were vaccinated with
GN2a cells that had been transfected 24 h previously
ith separate plasmids containing gene inserts for
D54 (pcDNA3.1/Hygro vector; Invitrogen), CD80,
D86, and CD137L (each in pCI-neo vectors; Pro-
ega, Madison, Wis) using nucleofection (Amaxa
iosystems, Koeln, Germany) as described previously
7]. Control mice were vaccinated with AGN2a cells
ucleofected with unmodiﬁed pcDNA3.1/Hygro and
CI-neo plasmids. One week to 3 wk after the last
accination, the mice were challenged subcutaneously
ith 103 to 5  106 viable AGN2a cells and followed
or tumor development. Mice were considered mori-
und and killed when a tumor exceeded 250 mm2.
In some experiments, mice were treated with 250
g of anti-CD25 mAb 4 d after HSCT. In other
xperiments, mice were depleted of T cell subsets in
ivo by treating them with subset-speciﬁc mAbs dur-
ng the induction or effector phases of the vaccine-
nduced immune response. Mice were injected i.p.
ith 250 g anti-CD4 (GK1.5) or anti-CD8 (2.43)
Abs on days 4, 7, 10, and 14 after HSCT (immunenduction phase experiments) or on days 32 and 35 cfter HSCT (immune effector phase experiments). To
ssess the involvement of T cell subsets in the induc-
ion phase of the vaccine-induced immune response,
he mice were challenged with viable tumor cells 1 wk
fter the second tumor vaccination. For the effector
hase experiments, the mice were challenged with
iable tumor cells 3 wk after the second tumor vacci-
ation.
FN- ELISPOT Assays
To assess numbers of tumor-speciﬁc IFN--se-
reting CD8 or CD4 T cells, enzyme-linked im-
unosorbent spot (ELISPOT) assays were done using
he Mouse IFN- ELISPOT Kit from BD Bio-
ciences Pharmingen. The numbers of spots were
uantitated with an ImmunoSpot Analyzer using in-
luded acquisition and analysis software (CTL Ana-
yzers, LLC, Cleveland, Ohio).
reg Cell Suppression Assays
To verify the suppressive activity of CD4CD25
cells, 5  104 CD4CD25 responder T cells were
lated in microtiter wells alone or with different num-
ers of CD4CD25 cells. CD4CD25 cells and
D4CD25 responder T cells were isolated from
plenocytes using the CD4CD25 Regulatory T Cell
solation Kit (Miltenyi Biotec) according to the manu-
acturer’s instructions. The levels of CD4CD25 T
ell enrichment were determined by ﬂow cytometric
nalysis. The enriched CD4CD25 T cells were typ-
cally96% pure (see Figure 7). Responder cells were
timulated with anti-CD3/anti-CD28 mAb-coated
ynabeads (DYNAL Biotech ASA, Oslo, Norway) at
bead-to-responder T cell ratio of 1:4. After 72 h of
ulture, 3H-thymidine was added to each well for an
dditional 18 h. 3H-thymidine incorporation was
easured on a -scintillation counter, and the results
ere expressed as mean counts per minute of triplicate
ells.
tatistics
Survival curves were compared by log-rank anal-
sis. Student t test was used to analyze the number of
cells. P .05 was considered statistically signiﬁcant.
ESULTS
eneration of Effective Antitumor Immunity
oon after HSCT Requires Adoptive Transfusion
f T Cells
We previously reported that transient transfection
f mouse neuroblastoma cells with plasmid DNA vec-
ors encoding a panel of immune stimulatory mole-
ules (CD54, CD80, CD86, and CD137L) generates a
ell-based vaccine capable of inducing potent antitu-
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W. Jing et al.280or T cell immunity [7]. In this study, we evaluated
hether this tumor vaccine could generate a protec-
ive antitumor immune response in syngeneic HSC
ransplant recipients if administered immediately after
ransplantation. Studies of T cell reconstitution in
ice that had been treated with lethal TBI and a
yngeneic HSCT showed that the immediate post-
ransplantation phase was accompanied by a signiﬁ-
ant T cell deﬁciency (data not shown). We hypoth-
sized that adoptive transfer of T cells would be
equired for the success of tumor vaccination in the
arly post-transplantaiton period. To test this hypoth-
sis, A/J mice were lethally irradiated 1 d before
SCT (day1), infused with 107 unmanipulated syn-
eneic BM cells on day 0, and infused with or without
 106 puriﬁed T cells (Thy1.2-enriched) at day 3.
ice were vaccinated subcutaneously with 2  106
igure 1. Generation of an effective antitumor immune response so
ecovery. Lethally irradiated A/J mice underwent transplantation w
hy1.2-enriched T cells. One week after HSCT, recipients were va
ucleofected to express CD54, CD80, CD86, and CD137L molec
ontrol empty plasmid vectors (empty vector vaccine), or not vaccin
ere challenged with 104 (A), 105 (B), or 106 (C) viable AGN2a ce
f 2 separate experiments.rradiated AGN2a tumor cells nucleofected to express cD54, CD80, CD86, and CD137L (designated as
P-AGN2a cells) on days 7 and 14 after HSCT. Con-
rol mice were vaccinated with AGN2a cells that were
ucleofected with equal amounts of “empty” plasmids
ie, containing no transgene inserts). Other controls
onsisted of nonvaccinated BM recipients. One week
fter the last vaccination, mice were challenged sub-
utaneously with 104, 105, or 106 viable AGN2a cells
nd followed for tumor development. Nonvaccinated
ice were unable to resist even the lowest challenge
ose of 104 AGN2a cells (Figure 1), and T cell transfer
ailed to protect these mice from tumor challenge.
umor vaccination without T cell adoptive transfer
lso failed to protect mice from tumor challenge. In
ontrast, mice given adoptive T cell transfer and vac-
ination with nucleofected 4P-AGN2a cells were sig-
iﬁcantly protected from tumor challenge at all 3
r HSCT required adoptive transfer of T cells to facilitate immune
syngeneic BM cells and 3 d later were given or not given 5  106
d twice weekly with 2  106 irradiated AGN2a cells that had been
-AGN2a vaccine), AGN2a cells that had been nucleofected with
o vaccine). One week after the last vaccination, all groups of mice
followed for tumor development. Data represent combined resultson afte
ith 107
ccinate
ules (4P
ated (n
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Immunity to Neuroblastoma after Syngeneic HSCT Using Novel Mouse Tumor Vaccine 281f mice challenged with 104, 105 and 106 AGN2a cells,
espectively; P  .001 versus nonvaccinated mice).
GN2a cells nucleofected with empty vectors also
igniﬁcantly enhanced the survival of adoptive T cell-
ransferred mice challenged with the lower doses of
04 or 105 tumor cells (88.9% and 33.3% of mice,
espectively; P .01; Figure 1A,B). Similar results had
een previously obtained when empty vector/nucleo-
ected AGN2a cells were tested as a vaccine in normal
ice without transplants [7]. These results conﬁrmed
ur hypothesis that T cell adoptive transfer is required
or tumor vaccination to be effective in mice soon
fter HSCT.
ptimal Tumor Vaccine-Induced Immunity was
btained using 2  107 Nonseparated Splenocytes
s the Source of T Cell Adoptive Transfer
Next we sought to determine whether “untouched”
cells, in the form of nonseparated splenocytes, would
e as effective at facilitating tumor immunity as puriﬁed
cells that had been positively selected by immunomag-
etic bead sorting. Mice were subjected to HSCT as
efore, but puriﬁed T cells (5  106) or splenocytes
2  107 or 4  107) were coinfused with the BM,
nstead of given 3 d after transplantation. A dose of
 106 T cells approximates the T cell content in 2
07 splenocytes (data not shown). On days 7 and 14
fter HSCT, the mice were vaccinated subcutaneously
ith 2  106 irradiated 4P-AGN2a cells. A control
roup of mice given HSCT, but no T cell transfer or
accine, was included in the experiments. All mice
ere challenged subcutaneously on day 21 after
SCT with 5  106 viable AGN2a cells. Adoptive
ransfer of 2  107 splenocytes appeared to provide a
etter vaccine-induced antitumor response than did
 106 puriﬁed T cells, as indicated by increased,
lthough not statistically different, survival (56% ver-
us 20% survival; P 	 .058; Figure 2). These results
uggested that the immunomagnetic positive selection
ad an effect on survival and/or function of the adop-
ively transferred T cells or that the splenocytes con-
ained non-T cells capable of increasing the vaccine-
nduced antitumor effect. Increasing the dose of
plenocytes given at the time of HSCT from 2  107
o 4  107 cells did not further improve survival after
umor challenge (Figure 2). Based on these results, a
impliﬁed protocol using 2  107 nonseparated
plenocytes as the source of T cell add-back was cho-
en for the remaining experiments in this study.
doptive Transfer of Splenocytes and BM from
onors with Established Tumors Generates
accine-Induced Antitumor Immunity
To more closely mimic the clinical setting and to
est if the presence of established AGN2a tumors
esults in tolerized tumor-reactive immune cells, mice rith established neuroblastoma were used as donors
or BMT and adoptive spleen cell transfer. A/J donor
ice were inoculated subcutaneously with 1  106
GN2a cells 12 days before BM and splenocyte har-
est. Lethally irradiated A/J recipients underwent
ransplantation with BM and splenocytes harvested
rom the tumor-bearing or non-tumor-bearing A/J
onors. At the time of tissue harvest, the tumor cell-
noculated mice had palpable tumors that were 100
m2; percentages of CD25Foxp3CD4 Treg cells
n the spleens of tumor-bearing mice were not signif-
cantly increased compared with those in tumor-free
ice (data not shown). Seven days after HSCT, re-
ipient mice were vaccinated with irradiated 4P-
GN2a cells twice weekly. Nonvaccinated mice were
ncluded as a control group. All mice were then chal-
enged subcutaneously with 106 AGN2a cells 7 d after
he second vaccination. The nonvaccinated control
ice rapidly died from tumor progression 2-3 wk after
umor challenge (Figure 3). In contrast, 81% of mice
iven an adoptive transfer of splenocytes from non-
umor-bearing mice survived the tumor challenge. Al-
hough recipients of splenocytes from tumor-bearing
onors had decreased survival compared with recipi-
nts of splenocytes from non-tumor-bearing donors
70% versus 81%), the decrease in survival was not
igniﬁcant. These results indicated that adoptive
ransfer of splenocytes from tumor-bearing mice did
ot signiﬁcantly compromise the ability to generate
accine-induced tumor immunity. Therefore, in the
igure 2. Adoptive transfer of nonseparated splenocytes provided a
etter vaccine-induced antitumor effect than did T cells puriﬁed by
ositive selection using immunomagnetic sorting. Lethally irradi-
ted A/J mice underwent transplantation with 107 syngeneic BM
ells with/without 5  106 positively selected Thy1.2 T cells, 2 
07 nonseparated splenocytes, or 4 107 nonseparated splenocytes.
ne week after HSCT, mice given adoptive T cell/spleen cell
ransfer were vaccinated twice weekly with 2  106 irradiated
P-AGN2a cells. One week after the second vaccination (day 21
fter HSCT) all mice were challenged with 5  106 viable AGN2a
ells. Data represent combined results of 2 or 3 separate experi-
ents, and groups consisted of 10-16 total mice per group.emaining experiments we used splenocytes from non-
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W. Jing et al.282umor-bearing mice as the source of adoptive cell
ransfer to simplify the experimental design.
nti-neuroblastoma Response Induced by
accination with 4P-AGN2a Cells Soon after
SCT Depends on CD4 and CD8 T Cells
To determine which T cells are responsible for the
rotective antitumor immune responses, mice were
epleted of CD4 or CD8 cells in vivo using mAbs. For
SCT, lethally irradiated A/J mice underwent trans-
lantation with BM cells admixed with 2  107
plenocytes from normal A/J donors. The trans-
lanted mice were vaccinated with nucleofected 4P-
GN2a cells on days 7 and 14 after HSCT. Anti-CD4
r anti-CD8 mAb was then administered during the
nduction phase (days 4, 7, 10, and 14 after HSCT) or
uring the effector phase (18 and 21 d after last vac-
ination and 32 and 35 d after HSCT). More than
9% of CD8 and 95% of CD4 T cells were de-
leted by the mAb treatment (data not shown). Mice
ere challenged with 106 live AGN2a cells 21 d (in-
uction phase) after HSCT or 5  105 live AGN2a
5 d (effector phase) after HSCT.
Approximately 80% of non-antibody-treated con-
rols survived the tumor challenge (Figure 4A,B). De-
letion of CD4 or CD8 T cells during the induction
igure 3. Antitumor immunity could be generated in HSC trans-
lant recipients given adoptive transfer of splenocytes from donors
ith established neuroblastoma. A/J mice were transplanted with
07 syngeneic BM cells and 2  107 splenocytes from normal mice
r mice with established neuroblastomas (see Methods for speciﬁcs).
rieﬂy, donor mice were inoculated with 106 AGN2a cells subcu-
aneously, and 12 d later BM and spleen cells were collected and
sed for HSCT. Recipients were vaccinated on days 7 and 14 after
SCT with 2  106 irradiated 4P-AGN2a cells. Mice were then
hallenged with 106 viable AGN2a tumor cells subcutaneously and
ollowed for survival. A group of nonvaccinated controls was in-
luded in the experiments. Data represent combined results of 2-3
eparate experiments, and groups consisted of 10-16 total mice per
roup.hase of the immune response signiﬁcantly reduced murvival of the vaccinated mice (P  .001; Figure 4A),
ndicating that both T cell subsets are important for
enerating the antitumor response.
As expected, CD8 T cells were found to be
mportant effectors of the antitumor immune re-
ponse (Figure 4B; P 	 .0001 versus non-antibody-
reated mice). However, CD4 T cells also appear to
lay a role in the effector phase of the immune re-
ponse because the ability to resist tumor challenge
as almost completely abrogated by treatment with
nti-CD4 mAb (Figure 4B; P 	 .002 versus non-
ntibody-treated mice).
mmunization with 4P-AGN2a Cells Elicits
umor-Reactive IFN--Producing CD4 and
D8 T Cells in HSC Transplant Recipients
T cell tumor reactivity elicited soon after HSCT
y 4P-AGN2a vaccination was assessed in vitro us-
ng IFN- enzyme-linked immunosorbent spot
ELISPOT) assays. Lethally irradiated mice under-
ent transplantation with BM with/without spleno-
ytes with/without tumor vaccination (days 7 and 14
fter HSCT). An additional control group consisted of
ontransplanted mice given 2 weekly vaccinations
ith 4P-AGN2a cells. Five days after the last vacci-
ation, spleens were harvested and CD4 and CD8
cells puriﬁed by immunomagnetic sorting. The
uriﬁed cells were then analyzed for the presence of
umor-reactive, IFN--producing cells in ELISPOT
ssays. Results of these assays, plotted as the number
f IFN- spots per 105 T cells, are shown in Figure 5.
ice given the combination of BM, spleen cells, and
accination had signiﬁcantly increased frequencies of
FN--producing, tumor-speciﬁc CD8 T cells com-
ared with mice given BM and vaccination (no spleen
ells), mice given BM and splenocytes without vacci-
ation, or nontransplanted/vaccinated mice (P  .001
r P  .01; Figure 5A). Post-HSCT vaccination with-
ut spleen cell adoptive transfer also had signiﬁcantly
ncreased CD8 IFN- spot frequencies compared
ith cells from nonvaccinated mice (P  .01; Figure
A). Relatively low CD8 IFN- spot frequencies
ere observed in response to the control MHC-
atched SaI tumor cells. The creation of MHC class
I AGN2a cells by stable transfection of the human
HC class II transactivator (CIITA) gene allowed us
o also assess tumor-reactive, IFN--producing CD4
cells by ELISPOT. We found that CD4 IFN-
pot frequencies in response to AGN2a-CIITA cells
ere signiﬁcantly higher in cells from mice given BM,
pleen cells, and vaccination than in cells from all
ther groups of mice, including the nontransplanted/
accinated group (P  .001; Figure 5B). Together,
esults of the ELISPOT assays conﬁrmed the involve-
ent of tumor-reactive CD4 and CD8 T cells in
he post-transplantation induction of antitumor im-
unity by the 4P-AGN2a tumor vaccine.
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plenic T cell subsets were also analyzed to compare
evels of T cell reconstitution between the experi-
ental groups. Adoptive transfer of splenocytes
ith HSCT accelerated T cell reconstitution as
eﬂected by signiﬁcantly increased splenic CD4 and
D8 T cell numbers compared with mice given
SCT only (Table 1). Further, HSC transplant
ecipients given adoptive T cell transfer and vacci-
ation had 10-20 times more tumor-reactive CD4
nd CD8 T cells in their spleens than did vaccinated
ice receiving only BM cells (data not shown).
ffects of Treg Inhibition in the HSC Transplant
ecipients or Physical Depletion of Treg Cells
rom the Transferred Donor-Derived
ymphocytes
CD4CD25Foxp3 regulatory T (Treg) cells
ave been found to be important suppressors of
mmune reactivity in different disease settings in-
luding cancer [19,20]. Experiments in our labora-
ory have found that a single treatment with anti-
igure 4. The anti-neuroblastoma immune response induced by ea
/J mice underwent transplantation with syngeneic 107 BM cells a
SCT with 2  106 irradiated 4P-AGN2a cells. In vivo depleting a
SCT (induction phase) and mice were challenged with 106 live AG
hase) and mice were challenged with 5  105 live AGN2a cells on
roups consisted of 10-15 total mice per group. Anti-CD4 or anti-C
uring the induction phase (A; P  .001 for anti-CD4 and anti-CD
f the immune response compared with untreated mice.D25 mAb before tumor vaccination augments Che antitumor response to AGN2a (manuscript in
ress). Because the persistence/presence of
D4CD25Foxp3 Treg cells could have a neg-
tive effect on our ability to effectively vaccinate
ice soon after HSCT, we wanted to (a) examine
hether these cells were able to survive lethal TBI
r expand soon after HSCT from donor-derived
ells and (b) test whether anti-CD25 mAb treatment
efore early post-HSCT tumor vaccination could
nhance the vaccine-induced immune response.
First, we assessed the effect of lethal TBI andHSCT
n host-derived, donor BM-derived, and donor spleen
ell-derived CD4CD25 and CD4Foxp3 cells. Le-
hally irradiated C57BL/6 recipient mice (Thy1.2/
D45.2) underwent transplantation with 107 BM
ells from B6.PL-Thy1a mice (Thy1.1/CD45.2)
lus 2  107 splenocytes from B6-CD45.1 mice
Thy1.2/CD45.1). Mice were killed on days 3, 7,
4, 21, 28, and 35 after HSCT, spleen cells were
solated and counted, and cells were analyzed by ﬂow
ytometry to determine percentages of CD4 cells
oexpressing CD25 or Foxp3 and absolute numbers of
-transplantation vaccination depends on CD4 and CD8 T cells.
107 splenocytes and were then vaccinated on days 7 and 14 after
4 or anti-CD8 mAbs were (A) given on days 4, 7, 10, and 14 after
ells on day 21 or (B) given on days 32 and 35 after HSCT (effector
5. Data represent combined results of 2 separate experiments, and
b treatment signiﬁcantly decreased the survival of vaccinated mice
ed mice) and effector phase (B; P  .01 or P  .001, respectively)rly post
nd 2 
nti-CD
N2a c
day 3
D8 mA
8 treatD4CD25 and CD4Foxp3 cells. Even though
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W. Jing et al.284hemice had been infused with 2 107 splenocytes, they
emained lymphopenic until 3 wk after transplantation
Figure 6A). The lymphopenia was reﬂected by low
plenic CD4 T cell numbers (Figure 6B). Only small
umbers of CD4CD25 and CD4Foxp3 cells could
e detected in the ﬁrst 2 wk after HSCT, and these cells
ere primarily host-derived on day 3 after HSCT, but
hey switched to being mostly derived from the adop-
ively transferred T cells by day 7 (Figure 6C,D).
nterestingly, residual host-derived CD4CD25 and
D4Foxp3 cells appeared to expand and/or accumu-
ate in the spleen 3-5 wk after HSCT. BM-derived
D4CD25 and CD4Foxp3 cells could not be de-
ected until 3 wk after HSCT, and they expanded in
umber, but still constituted only a minority of the total
igure 5. Vaccination with 4P-AGN2a cells soon after HSCT
licits tumor-reactive IFN--producing CD4 and CD8 T cells.
/J mice underwent transplantation with 107 syngeneic BM cells
lus 2  107 splenocytes (BM  S) or BM alone (BM  S). Mice
ere then vaccinated on days 7 and 14 after HSCT with CD54/
0/86/137L-AGN2a cells ( Vax) or not vaccinated ( Vax). A
roup of normal nontransplanted mice given 2 weekly tumor vac-
inations (No HSCT  Vax) was also included in the experiments
or comparison. Five days after the second vaccination, all mice
ere killed, splenic T cell subsets were isolated by immunomagnetic
orting, and CD8 (A) and CD4 (B) cells were assayed for tumor-
eactive IFN--secreting cell frequencies by ELISPOT. Data are
rom 1 of 2 replicate experiments. **P  .001 and *P  .01 versus
M  S  Vax; #P  .01.D4CD25 and CD4Foxp3 cells at 5 wk. This †mplies that no single time point in the HSCT pro-
edure can be assumed to be free of Treg inﬂuences.
In normal nontransplanted mice, it has been
hown that approximately 10% of splenic CD4 cells
oexpress CD25 or Foxp3 [21,22]. We observed sim-
lar percentages in the spleens of BM donors or recip-
ents (Figure 6E,F; day 0). During the 35-d period
fter HSCT, percentages of residual host CD4 cells
hat coexpressed CD25 or Foxp3 showed a biphasic
ncrease. The adoptively transferred CD4 cells
howed a gradual increase in CD25 expression over
ime, but they had a much more pronounced increase
n Foxp3 expression that peaked at approximately 35%
n day 21 after HSCT. These results indicated that,
espite the state of profound lymphopenia during
he ﬁrst 2 wk after HSCT, increased percentages of
plenic CD4 cells coexpressed CD25 and Foxp3,
epresenting an apparent skewing toward increased
ercentages of Treg cells in the residual host and
doptively transferred T cells. To test if the
D4CD25 cells present in mice soon after HSCT
ere capable of exhibiting regulatory (or suppressive)
unction, CD25 cells were isolated by immunomag-
etic sorting from normal mice (Figure 7; no HSCT)
r from mice given HSCT 14 d earlier with syngeneic
M cells plus 2  107 added splenocytes (Figure 7;
M  S). When the puriﬁed CD25 cells were ana-
yzed by ﬂow cytometry, cells were 99% CD25,
96% of cells expressed CD4, and 92% of cells were
oxp3 (Figure 7A). In functional assays, CD25 from
he mice given syngeneic HSCT (BM S) suppressed
he polyclonal proliferation of CD4CD25 re-
ponder cells as effectively as CD25 cells from nor-
al mice (no HSCT; Figure 7B), indicating that the
D4CD25Foxp3 Treg cells in mice given HSCT
ere functional.
Based on our observations, we hypothesized that
reatment of HSC transplant recipients with anti-
D25 mAb before tumor vaccination would result in
able 1. T Cell Reconstitution after HSCT
Cells per
Spleen (105)
Groups*
BM  S 
Vax
BM  S 
Vax
No HSCT 
Vax
D8 T cells 3.9  4.1 12.2  4.1† 57.6  11.1
D4 T cells 12.1  6.5 32.4  5.4† 99.7  16.4
Mice were transplanted with 107 syngeneic BM cells plus 2  107
splenocytes (BM  S) or BM alone (BM  S). Mice were then
vaccinated on days 7 and 14 after HSCT with CD54/80/86/
137L-AGN2a cells ( Vax). A group of normal nontransplanted
mice given 2 weekly tumor vaccinations (No HSCT  Vax) was
included in the experiments for comparison. Five days after the
second vaccination, spleens were collected and the absolute T
cell numbers were assessed. Data for each group represents the
mean absolute number of cells 
 SEM from 6-8 total mice
(combined from 2 independent experiments).P  .01, BM  S  Vax versus BM  S  Vax.
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is, lethally irradiated A/J mice were given HSCT with
M cells plus splenocytes. Some of the transplanted
ice were then treated with 250 g of anti-CD25
Ab 3 d before the ﬁrst of 2 weekly vaccinations with
D54/80/86/137L-AGN2a cells. The goal of this
trategy was to inhibit endogenous and infused
D25 Treg cells. Seven days after the second tumor
igure 6. CD4CD25Foxp3 T cells primarily derived from the
SCT. C57BL/6 (Thy1.2CD45.2) mice were lethally irradiated a
Thy1.1CD45.2) plus 2  107 splenocytes from congenic B6-C
oints and spleens were collected for analysis. (A) Nucleated cell nu
ytometry to assess absolute numbers of (B) CD4 cells, (C) CD4
ercentages of (E) CD4 cells coexpressing CD25 and (F) CD4
xpression, cells of donor BM origin, host origin, or cells derived f
and F represent percentages of CD4 cells in each cell compartm
erived from donor splenocyte, Spln donor). Data represent mean v
xperiment). ***P  .001; **P  .01; *P  .05 versus values from naccination, the HSC transplant recipients were chal- venged with 106 (Figure 8A) or 5  106 (Figure 8B)
ive AGN2a cells. Tumor vaccination signiﬁcantly
rotected mice from tumor challenge (all vaccinated
roups versus nonvaccinated group; P  .001). In
ontrast to previous results in normal mice, where
reatment with anti-CD25 mAb improved antitumor
mmunity (manuscript in press), anti-CD25 mAb
reatment soon after HSCT diminished the tumor
(splenocyte) adoptive transfer can be detected soon after syngeneic
h later injected with 107 BM cells from congenic B6.PL-Thy1a mice
mice (Thy1.2CD45.1). Mice were killed at the indicated time
ere counted, and the remaining splenocytes were analyzed by ﬂow
coexpressing CD25, and (D) CD4 cells coexpressing Foxp3, and
oexpressing Foxp3. Due to allelic differences in Thy1 and CD45
nor splenocytes could be distinguished from one another. Bars in
, derived from donor BM, BM donor; derived from host, Host; or
f 6 individual spleens from 2 experiments (3 individual spleens per
donor or host mice (day 0).T cell
nd 24
D45.1
mbers w
 cells
cells c
rom do
ent (ie
alues oaccine-induce immune response as indicated by de-
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Figure 7. CD4CD25 cells isolated from mice soon after HSCT exhibited regulatory function in vitro. CD4CD25 T cells were isolated from spleens of normal mice (No HSCT) or from
transplanted mice 14 d after HSCT with syngeneic BM cells plus 2  107 added splenocytes (BM  S). A, Purity of isolated cells was assessed by ﬂow cytometry, where CD4, CD25, and Foxp3
expressions are shown in 2-color histograms. B, In vitro suppressor assays were used to assess regulatory cell function. Brieﬂy, 5  104 CD4CD25 responder T cells were cocultured with 1.25 
104 anti-CD3/anti-CD28 mAb-coated Dynal beads plus the indicated ratios of puriﬁed CD4CD25 cells. 3H-thymidine incorporation is shown as mean counts per minute 
 SD of triplicate wells.
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n survival did not reach statistical signiﬁcance, the
esults suggested that our hypothesis was incorrect
nd further suggested that the anti-CD25 mAb treat-
ent might have inhibited CD25 effector T cells
enerated in the vaccinated hosts. To address this
ossibility, phenotypic and functional studies were
one on tissues of anti-CD25 mAb treated and vacci-
ated mice. Flow cytometric analysis of tissues
blood, lymph nodes, and spleen) from anti-CD25
Ab-treated mice 10 d after antibody treatment
ndicated that CD25 expression was signiﬁcantly
ecreased on CD4 cells (Table 2). Percentages of
oxp3CD4 T cells were also decreased in anti-
D25 mAb-treated mice compared with non-anti-
D25 treated mice, but to a lesser degree (Table 2).
esults of IFN- ELISPOT assays indicated that
igure 8. Treatment of HSC transplant recipients with anti-CD
nﬂuenced the antitumor response. A/J mice underwent transplanta
ice were vaccinated on days 7 and 14 after HSCT with irradiated
d before the ﬁrst vaccination. A group of nonvaccinated control m
A) 106 or (B) 5  106 viable AGN2a cells. Survival data represent co
n each group. C, CD4 T cells were isolated from vaccinated m
LISPOT assays to determine frequencies of INF--producing cel
ata are from 1 of 2 replicate experiments. *P  .05.arly post-HSCT anti-CD25 mAb treatment signif- 2cantly decreased the frequency of tumor-reactive
D4 T cells (Figure 8C).
As an alternative strategy to address the possible
nﬂuence of CD25 Treg cells on early post-HSCT
umor vaccination, we physically depleted CD25
ells from the adoptively transferred splenocytes
sing immunomagnetic sorting. This approach was
ased on results displayed in Figure 6C and 6D
howing that most CD4CD25Foxp3 cells soon
fter HSCT were derived from the adoptively
ransferred T cells. Immunomagnetic sorting elimi-
ated 95% of the CD25 T cells in the trans-
erred population and approximately 70% of
oxp3CD4 T cells (data not shown). Lethally irra-
iated A/J mice were given HSCT with BM cells
dmixed with nondepleted splenocytes or splenocytes
epleted of CD25 cells. Fourteen days or 21 d after
b before early post-transplantation tumor vaccination negatively
th 107 syngeneic BM cells plus 2  107 splenocytes. Transplanted
N2a cells. Some recipient mice were treated with anti-CD25 mAb
s included. Mice were then challenged on day 21 after HSCT with
d results of 2-3 separate experiments, including a total of 9-16 mice
after the initial vaccination (day 14 after HSCT) and tested in
sponse to MHC class II (AGN2a-CIITA) tumor cells. ELISPOT25 mA
tion wi
4P-AG
ice wa
mbine
ice 7 d
ls in reweekly vaccinations with 4P-AGN2a cells, the HSC
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W. Jing et al.288ransplant recipients were challenged with 5 106 live
GN2a cells. Recipients of CD25-depleted spleno-
ytes had better survival than did recipients of nonde-
leted splenocytes (77% versus 50%; Figure 9), but
he increased survival did not reach statistical signiﬁ-
ance (P 	 .14).
To determine the inﬂuence of CD25 depletion on
D25Foxp3CD4 cell reconstitution, percentages
f CD25CD4 and Foxp3CD4 in blood, lymph
odes, and spleen were examined (Table 2). Two
eeks after HSCT and adoptive transfer of spleno-
ytes, both groups of mice ((BMS  S [CD25 depl]
ersus BM  S) contained similar percentages of
oxp3CD4 and CD25CD4 T cells in the
able 2. Treg Cell Reconstitution after HSCT
Treg Subset Tissue BM  S BM  S (C
D25 CD4 Blood 42.9  4.1 40.7 
LN 22.0  1.4 22.0 
Spleen 44.0  1.1 38.4 
oxp3 CD4 Blood 43.0  5.4 40.0 
LN 21.6  0.9 20.3 
Spleen 43.0  1.0 35.2 
N indicates lymph node.
Mice were transplanted with 107 syngeneic BM cells plus 2  107
[CD25 depl]). Some mice transplanted with BM cells and spleno
S  anti-CD25 mAb). Normal nontransplanted mice were inclu
Data for each group represent mean percentages of CD4 cells t
group (combined from 2 independent experiments).
P  .05; ‡P  .01, BM  S versus BM  S (CD25 depl).
P  .05; P  .01, BM  S versus BM  S  anti-CD25 mAb.
igure 9. Adoptive transfer of CD25-depleted splenocytes at time
f HSCT resulted in increased tumor vaccine efﬁcacy. A/J mice
nderwent transplantation with 107 syngeneic BM cells plus 2 107
onseparated splenocytes or splenocytes depleted of CD25-positive
ells by immunomagnetic depletion. Transplanted mice were vac-
inated on days 7 and 14 after HSCT with irradiated 4P-AGN2a
ells. All mice were then challenged on day 14 or 21 after the last
accination with 5  106 viable AGN2a cells. Data represent com-
ined results of 2 separate experiments. Groups consisted of 10-13cotal mice per group.lood and lymph nodes, but decreased percentages
f Foxp3CD4 and CD25CD4 T cells were
etected in the spleens of mice given CD25-de-
leted splenocytes. These results suggested that
D25Foxp3CD4 cells in the transferred spleno-
ytes expanded and upregulated expression of CD25.
his also indicates that optimization of Treg cell de-
letion from a transferred T cell population awaits the
evelopment of cell surface markers others than
D25.
ISCUSSION
Adoptive cellular therapy in the context of HSCT
as the potential to boost the effectiveness of cell-
ased cancer vaccines. In this study, we tested whether
accination with genetically modiﬁed neuroblastoma
ells could generate anti-neuroblastoma immunity
hen administered early (ie, during the ﬁrst 2 wk)
fter lethal irradiation and syngeneic HSCT. We dis-
overed that potent antitumor immunity could be
enerated early after HSCT; however, the transplant
ecipients also required an adoptive transfer of T cells
or the vaccine to be effective.
Tumor vaccination 3-6 wk after HSCT in mice
ad been shown by others to induce a superior anti-
umor immune response compared with vaccination
f nontransplanted animals [15]. In contrast, immedi-
te post-transplantation vaccination (1-2 wk after
SCT) in those experiments showed no signiﬁcant
umor rejection due to a state of profound immune
eﬁciency. Another report showed that antitumor im-
une responses could be elicited by a tumor lysate-
ulsed dendritic cell vaccine initiated on day 7 after
MT without adoptive transfusion of T cells [17].
owever, success of the vaccine depended on the
resence of mature T cells in the transplanted BM and
Group*
epl) BM  S  anti-CD25 mAb Normal controls
1.4  1.2 7.6  1.1
8.4  3.4 12.5  0.1
1.2  0.2 13.5  1.4
36.7  4.0 7.9  1.0
17.6  0.3§ 12.1  0.2
33.0  0.1 13.4  0.9
cytes (BM  S) or BM plus CD25-depleted splenocytes (BM  S
ere treated with 250 g anti-CD25 mAb 4 d after HSCT (BM 
a control group. Tissue samples were collected 14 d after HSCT.
xpressed CD25 or Foxp3 
 SEM; 6-8 mice were analyzed for eachD25 d
4.7
1.7
1.3†
6.5
0.6
0.8‡
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Immunity to Neuroblastoma after Syngeneic HSCT Using Novel Mouse Tumor Vaccine 289ations. Our results show that adoptive transfer of
yngeneic T cells plus tumor vaccination facilitates the
eneration of a protective antitumor response (Figure 1).
he adoptively transferred T cells accelerated T cell
econstitution (Table 1), and the frequencies of tu-
or-reactive CD4 and CD8 T cells in the spleens
f transplanted/vaccinated mice were signiﬁcantly in-
reased compared with nontransplanted mice (Figure
), suggesting that the immune response was more
ffectively driven toward tumor reactivity by early
ost-transplantation vaccination. Similar to our re-
ults in nontransplanted mice [7], vaccination with
umor cells that had been nucleofected with “empty”
lasmid vectors also protected mice from lower tumor
hallenge doses (Figure 1A,B). Nucleofection with
mpty vectors did not induce any change in MHC
lass I or II, CD54, CD80, CD86, or CD137L mol-
cule expression on the tumor cell surface (data not
hown). One explanation for the increased tumor
mmunity is that the bacterial plasmid backbones
ontain immunostimulatory CpG motifs. It has
een shown that 1 plasmid vector used in our ex-
eriments (pCDNA3 vector) contains immunostimu-
atory CpG motifs [23], and CpG motifs have been
reviously shown by investigators to facilitate the ac-
ivation of innate and acquired immune responses
oward tumors [24]. As previously documented, the
ucleofection process results in the immediate intro-
uction of thousands of plasmid DNA copies into
ach cell [7], making this explanation plausible.
Our results are clinically relevant because autolo-
ous HSCT in patients is similarly accompanied by a
eriod of pronounced immune deﬁciency. After autol-
gous HSCT, patients typically have low lymphocyte
ounts and impaired T cell immune function during
he ﬁrst 3 mo after transplantation [10], and attempts
o vaccinate soon after transplantation are likely ham-
ered due to the immune deﬁcient state. Early post-
ransplantation immune deﬁciency may also contrib-
te to increased risk of relapse from minimal residual
isease. Retrospective studies have suggested that su-
erior clinical survival may be associated with more
apid lymphocyte recovery after transplantation. The
ate of immune reconstitution has been shown to be
n independent marker of time to progression in
atients with advanced ovarian cancer after PBSCT
25]. A recently published randomized clinical study
howed that a single early post-transplantation in-
usion of vaccine-primed and costimulated autolo-
ous T cells in conjunction with immunization im-
roves post-transplantation immunodeﬁciency and
an facilitate the generation of pneumococcal im-
unity [26]. The results of these 2 studies suggest
hat a rapid post-transplantation recovery of the
mmune system in a situation of minimal residual
isease will be a prerequisite for effective antitumor
mmunotherapy. Further, they demonstrate the fea- fibility of T cell adoptive transfer at the time of or
oon after HSCT.
Immune tolerance is a major barrier to effective
mmunization against tumor, and tumor establish-
ent has been associated with tolerance to tumor
ntigens [27,28]. Our results demonstrated that im-
une cells from mice with established tumors were
apable of facilitating vaccine-induced neuroblastoma
mmunity soon after HSCT (Figure 3). The spleno-
ytes used for adoptive transfusion were collected
rom mice with 100 mm2 12-d AGN2a tumors. Al-
hough it has been shown in other mouse cancer
odels that tumor progression can be accompanied by
ncreased frequencies of Treg cells in peripheral lym-
hoid tissues [29,30], we detected no signiﬁcant in-
rease in CD25Foxp3CD4 Treg cells in the
pleens of mice bearing 12-d AGN2a tumors. Further,
e were unable to detect increased percentages of
D25Foxp3CD4 Treg cells in the spleens of
ice bearing larger AGN2a tumors 250 mm2 (un-
ublished data). Although our data suggest that tu-
or-reactive T cells in mice with established neuro-
lastoma are not eliminated or irreversibly tolerized in
he peripheral lymphoid tissues, we cannot rule out
he possibility that results would be different in mice
earing even larger tumor burdens. We currently hy-
othesize that immunization with our cell-based vac-
ine during the process of homeostatic expansion soon
fter HSCT facilitates activation and proliferation of
ow-afﬁnity tumor-reactive T cells [31-35] and that
his allows “tolerized” T cells to react against tumor-
elf antigens. These data have important implica-
ions as we tailor our future studies toward a model
f established neuroblastoma, where we plan to test
reatment of tumor-bearing mice with the combi-
ation of high-dose therapy, HSCT, adoptive im-
unotherapy (with cells from tumor-bearing do-
ors), and tumor vaccination.
CD8 and CD 4 T cells are involved in the effector
hase of the vaccine-induced immune response soon
fter HSCT (Figure 4B). This was surprising because
he AGN2a tumor cells do not express MHC class II
olecules. We speculate that the involvement of
D4 T cells in the effector response could be (a) by
roviding helper activity to aid in the prompt activa-
ion of CD8 cytotoxic effector cells or tissue macro-
hages or (b) by directly serving as effector cells
hrough tumoricidal cytokine production. Mecha-
isms that have been previously implicated in CD4
ntitumor effector function include secretion of
FN-, which has been shown to mediate tumor re-
ection by its antitumor and antiangiogenic properties
36,37], or activation of macrophages capable of sup-
ressing tumor growth [38,39].
Animal data from Antony et al [40] suggested that
maller numbers of Treg cells are in part responsible
or the enhanced efﬁcacy of tumor immunotherapy in
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W. Jing et al.290ymphodepleted hosts. It has been shown that deple-
ion or inhibition of CD4CD25 cells by anti-CD25
Ab administration can enhance tumor rejection
41-43], and that tumor vaccination combined with
reg cell depletion/inhibition can increase vaccine
fﬁcacy [44,45]. Recently, we found that anti-CD25
Ab treatment can improve vaccine-induced antitu-
or responses to AGN2a (manuscript in press). In the
resent report, we investigated the effect of lethal
BI, HSCT, and adoptive T cell transfer (spleno-
ytes) on CD4CD25 and CD4Foxp3 cells of
ost and donor origin. As far as we aware, this is the
rst time this type of detailed study has been done in
ice soon after HSCT. During the period of T cell
ymphopenia soon after HSCT, increased percentages
f splenic CD4CD25Foxp3 cells capable of elic-
ting functional Treg activity (Figure 7) were observed
n mice transplanted with BM and splenocytes, and
ost of these cells appeared to be derived from the
ransferred T cells (Figure 6). However, anti-neuro-
lastoma immunity could still be efﬁciently induced
oon after HSCT. Due to the increased frequency of
D4CD25Foxp3 cells, we wished to determine
f inhibition of residual Treg cells could further
nﬂuence vaccine efﬁcacy. To do this, we tried 2
ifferent strategies. First, we treated HSC recipi-
nts with anti-CD25 mAb before the initial tumor
accination because this same strategy had increased
accine-induced immunity in normal mice (unpub-
ished observations). In the second approach,
D25-positive cells in the adoptively transferred
plenocytes were physically depleted before infusion.
reatment of HSC recipients with anti-CD25 mAb
egatively inﬂuenced vaccine-induced antitumor im-
unity (Figure 8A,B), suggesting that the antibody
reatment inhibited effector cell function in this set-
ing. To support this conclusion, IFN- ELISPOT
nalysis demonstrated that in vivo anti-CD25 mAb
reatment resulted in decreased numbers of tumor-
eactive CD4 T cells in vaccinated HSC recipients
Figure 8C). It is unclear why prevaccination anti-
D25 treatment inhibits immune effector cells in the
arly post-HSCT setting but enhances tumor reactiv-
ty in the normal setting. Perhaps the difference is
elated to increased expression of IL-2 receptors on T
ells in a lymphopenic environment [46].
Different results were seen in experiments testing
he second strategy because infusion of CD25-de-
leted splenocytes increased survival of tumor-vacci-
ated mice (Figure 9). Although depletion of the
D25-positive cells from adoptively transferred cells
id not inﬂuence the percentages of Foxp3CD4
ells in the peripheral blood or lymph nodes 14 d after
SCT, percentages of Foxp3CD4 cells were sig-
iﬁcantly decreased in the spleen (Table 2). Unfortu-
ately, we did not evaluate the tissues at earlier time
oints, and we may have missed more profound dif-erences early on that could inﬂuence tumor vaccina-
ion. As a cautionary note, the increased survival of
ice receiving CD25-depleted splenocytes (27% in-
rease over mice given nondepleted splenocytes) was
ot statistically signiﬁcant. Because approximately
0% of Foxp3CD4 cells do not coexpress CD25, it
s possible that elimination of these cells and
D25Foxp3CD4 cells from the adoptively trans-
erred T cells by some other means would further
nhance tumor immunity. More speciﬁc Treg cell
eagents are clearly needed to better target these cells
or elimination/inhibition.
In summary, our results demonstrate that anti-
euroblastoma immunity can be induced soon after
SCT by tumor vaccination, but sufﬁcient numbers
f T cells must be included in the graft to achieve
rotective antitumor immunity. CD4 and CD8 T
ells are involved in the induction and effector phases
f the vaccine-induced immune response, and early
ost-HSCT vaccination resulted in increased frequen-
ies of tumor-reactive T cells compared with non-
ransplanted mice that had been vaccinated. Although
ercentages of Foxp3CD25CD4 T cells were in-
reased soon after HSCT, protective tumor immunity
ould still be induced. However, elimination of CD25
ells from splenocytes (as a source of T cells) added to
he graft appears to enhance vaccine efﬁcacy. These
esults provide experimental data in support of a mul-
ifaceted clinical approach for the treatment of neu-
oblastoma combining high-dose therapy, autologous
SCT, adoptive immunotherapy (T cell add-back),
nd post-transplantaion tumor vaccination.
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